培米替尼国内哪里买的到？

In 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Incyte for the treatment of adult patients with previously treated advanced cholangiocarcinoma. This is the world's first targeted therapy for cholangiocarcinoma.

The approval of pemetinib was based on the results of a clinical trial involving 107 patients with locally advanced or metastatic cholangiocarcinoma. These patients have been previously treated and carry FGFR2 (fibroblast growth factor receptor 2) fusions or rearrangements.

The trial results showed that the overall response rate (ORR) of pemetinib reached 36%, of which 2.8% of patients had complete response and 33% of patients had partial response. Of the 38 patients who experienced a response, 24 patients (63%) had a response that lasted 6 months or longer, and 7 patients (18%) had a response that lasted 12 months or longer.

In patients receiving pemetinib, the most common adverse reactions were: hyperphosphatemia and hypophosphatemia (electrolyte imbalance), alopecia (bald patches), diarrhea, indigestion, nausea, nail toxicity, fatigue, constipation, stomatitis (20% or more), pain or inflammation in the mouth, dry eye, vomiting, joint pain, dry mouth, decreased appetite, abdominal pain, back pain, and dry skin. Ocular toxicity is also a risk with Pemazyre.

Pemetinib belongs to a class of drugs called kinase inhibitors. It works by blocking the action of abnormal proteins that signal cancer cells to multiply. This helps prevent or slow down the spread of cancer cells. Where can I buy pemetinib in China?

It is understood that it has not been officially launched in China, so it has not been displayed and sold in China. Patients in need can purchase the version launched abroad. For specific matters related to purchasing pemetinib, you can consult the medical companion at any time!

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: